A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN) (ODIN)

February 12, 2013 updated by: Tibotec Pharmaceuticals, Ireland

A Randomized, Open-label Trial to Compare the Efficacy, Safety and Tolerability of DRV/Rtv (800mg/100mg) q.d Versus DRV/Rtv (600mg/100mg) b.i.d in Early Treatment-experienced HIV-1 Infected Subjects

The purpose of this study is to test if being treated with darunavir/ritonavir (DRV/rtv) 800/100 mg daily is as effective as being treated with DRV/rtv 600/100 mg twice daily, in early antiretroviral (ARV)-experienced patients when given along with selected optimized background regimen (OBR).

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This is a randomized (the study medication is assigned by chance), open-label (all people know the identity of the intervention) study in which 590 patients will be randomly assigned to receive either DRV/rtv 800/100 mg daily or DRV/rtv 600/100 mg twice daily along with the selected OBR. An OBR will consist of at least 2 nucleoside reverse transcriptase inhibitors (NRTIs) selected by the investigator. The study will include a 4 week screening period, 48-weeks of treatment period and 4-weeks of follow-up. The study will also consists of extension phase after Week 48: in regions where DRV is not yet commercially available or reimbursed by the health care system, patients who complete the 48 weeks of treatment with DRV/rtv and who continue to benefit from this treatment, will have the opportunity to continue DRV treatment as a 600 mg twice daily dosage until DRV is reimbursed and available via the public and/or private health care system or until its development is discontinued. Safety evaluation will consists of adverse events (including specific toxicities), clinical laboratory tests, vital signs, electrocardiogram, physical and skin examination.

Study Type

Interventional

Enrollment (Actual)

590

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Argentina
      • Buenos Aires, Argentina
      • Cordoba, Argentina
      • Guernica, Argentina
      • Neuquen, Argentina
      • Rosario, Argentina
  • Australia
      • Darlinghurst, Australia
      • Surry Hills, Australia
  • Austria
      • Wien, Austria
  • Brazil
      • Curitiba, Brazil
      • Distrito Barao Geraldo-Campina, Brazil
      • Pinheiros, Brazil
      • Recife, Brazil
      • Rio De Janeiro, Brazil
      • Salvador, Brazil
      • Sao Paulo, Brazil
  • Chile
      • Providencia, Chile
      • Santiago, Chile
  • France
      • Lyon, France
      • Nice, France
      • Orleans Cedex 2, France
      • Paris, France
      • Paris Cedex 10, France
      • Paris Cedex 12, France
      • Vandoeuvre Les Nancy, France
  • Germany
      • Berlin, Germany
      • Köln, Germany
      • München, Germany
  • Guatemala
      • Guatemala, Guatemala
  • Hungary
      • Budapest, Hungary
  • Malaysia
      • Ipoh, Malaysia
      • Kuala Lumpur, Malaysia
      • Pulau Pinang, Malaysia
      • Sungai Buloh, Malaysia
  • Panama
      • Panama, Panama
  • Puerto Rico
      • San Juan, Puerto Rico
  • Romania
      • Bucuresti, Romania
      • Constanta, Romania
      • Iasi, Romania
      • Timisoara, Romania
  • South Africa
      • Cape Town, South Africa
      • Cyrildene Johannesburg Gauteng, South Africa
      • Dundee, South Africa
      • Durban, South Africa
      • Houghton, Johannesburg, South Africa
      • Johannesburg, South Africa
      • Pretoria, South Africa
      • Westdene Johannesburg Gauteng, South Africa
  • Spain
      • Barcelona N/A, Spain
      • Madrid, Spain
  • Taiwan
      • Kaohsiung County, Taiwan
      • Taichung 407, Taiwan
      • Taipei, Taiwan
  • Thailand
      • Bangkok, Thailand
      • Chiang Mai, Thailand
      • Khon Kaen, Thailand
      • Nonthaburi, Thailand
  • United Kingdom
      • London, United Kingdom
  • United States
    • Arizona
      • Phoenix, Arizona, United States
    • Arkansas
      • Little Rock, Arkansas, United States
    • California
      • Beverly Hills, California, United States
      • Oakland, California, United States
      • Palm Springs, California, United States
    • Florida
      • Fort Lauderdale, Florida, United States
      • Fort Laudersale, Florida, United States
      • Miami, Florida, United States
      • Miami Beach, Florida, United States
      • Orlando, Florida, United States
      • Safety Harbor, Florida, United States
      • West Palm Beach, Florida, United States
    • Georgia
      • Atlanta, Georgia, United States
      • Macon, Georgia, United States
      • Savannah, Georgia, United States
    • Illinois
      • Chicago, Illinois, United States
    • Massachusetts
      • Springfield, Massachusetts, United States
    • Michigan
      • Berkley, Michigan, United States
    • New Jersey
      • Newark, New Jersey, United States
    • New York
      • Albany, New York, United States
      • Bronx, New York, United States
      • New York, New York, United States
      • Rochester, New York, United States
    • North Carolina
      • Huntersville, North Carolina, United States
      • Winston Salem, North Carolina, United States
    • Ohio
      • Akron, Ohio, United States
    • South Carolina
      • Charleston, South Carolina, United States
    • Texas
      • Dallas, Texas, United States
      • Harlingen, Texas, United States
      • Houston, Texas, United States

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients with documented human immunodeficiency virus - Type 1 (HIV-1) infection
  • Patients with a viral load greater than 1,000 HIV-1 ribonucleic acid (RNA) copies/mL
  • Stable highly active antiretroviral therapy (HAART) regimen for at least 12 weeks at screening
  • In the investigator's opinion, non-nucleoside reverse transcriptase inhibitors (NNRTIs) are not a valid treatment option, because of the patient's antiretroviral (ARV) treatment history, ARV resistance testing, medication-taking behavior, safety and tolerability concerns, or other patient-related factors
  • Prescreening or/and screening plasma HIV-1 RNA greater than 1,000 copies/mL on HAART regimen at screening

Exclusion Criteria:

  • Presence of any currently active conditions that fit the definition of the World Health Organization (WHO) Clinical Stage 4, with the following exceptions: stable cutaneous kaposi's sarcoma (ie, no internal organ involvement other than oral lesions) that is unlikely to require any form of systemic therapy during the study time period, wasting syndrome
  • Patients for whom an investigational ARV is part of the current regimen, with the following exceptions if applicable (depending on local regulatory approval): tenofovir, emtricitabine
  • Previous or current use of enfuvirtide (ENF), tipranavir and/or DRV
  • Life expectancy of less than 12 months
  • Pregnant or breast-feeding females
  • Any active clinically significant disease (eg, tuberculosis [TB], cardiac dysfunction, pancreatitis, acute viral infections) or findings during screening of medical history or physical examination that, in the investigator's opinion, would compromise the patient's safety or outcome of the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: DRV/rtv 800/100 mg once daily
Two 400 mg darunavir (DRV) ie, TMC114 tablets + one 100 mg ritonavir (rtv) capsule once daily.
Drug: Darunavir (DRV)
DRV/rtv 800/100 mg once daily group: 2 tablets of 400 mg of DRV administered orally once daily. DRV/rtv 600/100 mg twice daily group: 1 tablet of 600 mg DRV administered orally twice daily.
Other Names:
  • TMC114
Drug: Ritonavir (rtv)
DRV/rtv 800/100 mg once daily group: One capsule of 100 mg of ritonavir administered orally once daily. DRV/rtv 600/100 mg twice daily group: One capsule of 100 mg of ritonavir administered orally twice daily.
Other Names:
  • rtv
EXPERIMENTAL: DRV/rtv 600/100 mg twice daily
One 600 mg TMC114 tablet + one 100 mg capsule of rtv twice daily.
Drug: Darunavir (DRV)
DRV/rtv 800/100 mg once daily group: 2 tablets of 400 mg of DRV administered orally once daily. DRV/rtv 600/100 mg twice daily group: 1 tablet of 600 mg DRV administered orally twice daily.
Other Names:
  • TMC114
Drug: Ritonavir (rtv)
DRV/rtv 800/100 mg once daily group: One capsule of 100 mg of ritonavir administered orally once daily. DRV/rtv 600/100 mg twice daily group: One capsule of 100 mg of ritonavir administered orally twice daily.
Other Names:
  • rtv

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Virological Response at Week 48 (Number of Participants With Plasma Viral Load Less Than 50 Copies/mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm
Time Frame: 48 Weeks
The TLOVR algorithm was used to derive response, ie, response and loss of response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders after discontinuation. Participants with intermittent missing viral load values were considered responders if the preceeding and succeeding visits indicated response. In all other cases, intermittent values were imputed with nonresponse. Resuppression after confirmed virologic failure was considered as failure in this algorithm.
48 Weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Virologic Response at Week 48 (Viral Load Less Than 400 Copies/mL)
Time Frame: 48 weeks
Number of participants with confirmed plasma viral load less than 400 copies/mL at Week 48.
48 weeks
Change in log10 Viral Load From Baseline at Week 48
Time Frame: 48 weeks
48 weeks
Time to Reach First Virologic Response
Time Frame: 48 weeks
Time (in weeks) to achieve viral load less than 50 copies/mL by the participants.
48 weeks
Time to Loss of Virologic Response
Time Frame: 48 weeks
Time taken to lose the virologic response ie, plasma viral load less than 50 copies/mL by participants.
48 weeks
Time-averaged Difference (DAVG) of log10 Plasma Viral Load Over 48 Weeks
Time Frame: 48 weeks
48 weeks
Change in CD4+ Cell Count From Baseline
Time Frame: 48 Weeks
CD4+ cell count was calculated using the Last Observation Carried Forward (LOCF) algorithm.
48 Weeks
Change From Baseline in Total Functional Assessment of HIV Infection (FAHI) Score
Time Frame: 48 weeks
The FAHI is a 44-item questionnaire and incorporates 5 functional scales (physical well-being, emotional well-being/living with HIV, functional and global well-being, social well-being, and cognitive functioning). Each scale included several questions (all 5 scales include total 44 questions). For each question, participants gave a score of either 0 (not at all), 1 (a little bit), 2 (somewhat), 3 (quite a bit) and 4 (very much). Total FAHI imputed score is calculated by adding scores for each question. The range of total FAHI score is 0 to 176. Higher scores indicate worsening.
48 weeks
Percentage of Participants Adherent/Non-adherent to ARV as Determined by Modified Medication Adherence Self Report Inventory (M-MASRI) Questionnaire at Week 48
Time Frame: 48 weeks
Self-reported adherence to the ARV medications was measured. The M-MASRI asks participants to report the number of doses taken, as well as the number of doses taken during the last 30 days prior to the study visit by means of a horizontal visual analogue scale (VAS) that generates a self-rated percentage of doses of all the ARV medications taken during the past 30 days.
48 weeks
Area Under the Curve From the Time of Study Medication Administration Upto 24 Hour Postdose (AUC24h) of DRV and Rtv
Time Frame: 0 hour predose and 1 hour post dose measured at Weeks 4 and 24. Any time point measured at Weeks 8 and 48.
Pharmacokinetic parameter AUC24h was assessed from the time of study medication administration upto 24 hour postdose. Population Pharmacokinetic Estimates of DRV and rtv were evaluated.
0 hour predose and 1 hour post dose measured at Weeks 4 and 24. Any time point measured at Weeks 8 and 48.
Predose Plasma Concentration (C0h) of DRV and Rtv.
Time Frame: 0 hour predose and 1 hour post dose measured at Weeks 4 and 24. Any time point measured at Weeks 8 and 48
Pharmacokinetic parameter C0h was assessed. Population Pharmacokinetic Estimates of DRV and rtv were evaluated.
0 hour predose and 1 hour post dose measured at Weeks 4 and 24. Any time point measured at Weeks 8 and 48
Number of Participants Developing Mutations at Endpoint
Time Frame: 48 weeks
Development of Mutations in Virologic Failures (Plasma Viral Load less than 50 Copies/mL) at endpoint.
48 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Tibotec Pharmaceuticals, Ireland

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2007

Primary Completion (ACTUAL)

August 1, 2009

Study Completion (ACTUAL)

October 1, 2011

Study Registration Dates

First Submitted

August 30, 2007

First Submitted That Met QC Criteria

August 30, 2007

First Posted (ESTIMATE)

September 3, 2007

Study Record Updates

Last Update Posted (ESTIMATE)

February 15, 2013

Last Update Submitted That Met QC Criteria

February 12, 2013

Last Verified

February 1, 2013

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CR013783
  • TMC114-TiDP31-C229 (OTHER: Tibotec Pharmaceuticals, Ireland)
  • 2007-001939-61 (EUDRACT_NUMBER)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Human Immunodeficiency Virus - Type 1

Clinical Trials on Darunavir (DRV)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe